# Novexel

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novexel

- Industry: Pharmaceuticals
- Headquarters: Romainville, France
- Website: www.novexel.com
- Total disclosed funding: $120M
- Latest round: Series B (Jan 8, 2007)
- Investors on record: 9

## About

Novexel SA is a French company specializing in domain valuation services, providing efficient market price assessments for domain names through a streamlined online platform.Novexel SA, founded in 2004 and headquartered in Romainville, France, specializes in domain valuation. The firm has engaged in 5 deals and achieved a significant milestone with a TRADE SALE that raised USD 505.00 mn, with AstraZeneca as one of the investors. No notable pivots in business strategy have been reported.Novexel specializes in providing domain valuation services, assisting customers in determining the market price of their domain names efficiently. Their core offering allows clients to submit a request for a price quote through an online form, with a commitment to deliver results within 24 business hours. This service primarily targets businesses, entrepreneurs, and individuals looking to buy or sell domain names, streamlining the process of domain valuation for users who may lack expertise in the market. Novexel serves a diverse client base across various geographical markets, focusing on North America, Europe, and select regions in Asia, catering to a wide range of end users who are engaged in digital marketing, e-commerce, and brand establishment.Novexel generates revenue through its domain valuation service, which operates on a transactional model where clients pay for evaluations based on specific requests. Customers submit their domain for assessment, and upon approval, they receive a pricing quote. The structure of these transactions is typically direct-to-consumer, allowing individuals and businesses to engage with the service without intermediary involvement. While specific pricing plans for services offered by Novexel are not disclosed, the company features various tiers of service based on the complexity of the domain evaluation, enabling a flexible pricing structure that aligns with the needs of different clients, including startups and established enterprises seeking to optimize their online presence.Going forward, Novexel plans to expand its service offerings and develop new products aimed at enhancing domain valuation accuracy and client engagement. The company is focusing on entering additional markets in Asia and Europe by late 2024, utilizing the funds from the recent TRADE SALE to support these initiatives. Furthermore, the exit of Ampersand Capital Partners from Novexel highlights the company’s evolving structure, which may influence its strategic direction in future market engagements.

## Funding rounds

- Series B, Jan 8, 2007, $66M — 3i, Abingworth, Atlas Venture, Sofinnova Partners, Andera Partners, Daiwa Corporate Investment, NeoMed, Goldman Sachs Asset Management, Novo Holdings A/S
- Series A, Dec 3, 2004, $54M — 3i, Abingworth, Atlas Venture, Sofinnova Partners, Novo Holdings A/S

## Investors

- 3i (https://capitalatlas.ai/funds/3i) — Series A, Series B
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Novo Holdings A/S — Series A, Series B
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series B
- NeoMed (https://capitalatlas.ai/funds/neomed) — Series B
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series B